Insulin pump therapy for diabetes mellitus: nothing new, though familiar
https://doi.org/10.21518/2079-701X-2013-6-92-98
Abstract
Diabetes mellitus (DM) is one of the most common chronic diseases worldwide. According to the International Diabetes Federation (IDF), the number of adult patients (20-79 years) will reach 552 million people by 2030 globally[1]. Achieving and maintaining a stable blood glucose concentration closest to the physiological standards is the main goal of DM therapy[2]. Insulin therapy is the only effective treatment for diabetes mellitus type 1; in addition, many people with DM 2 and other types one day reach a point at which insulin becomes the only way to achieve the goal of treatment. Continuous subcutaneous insulin infusion (CSII) is a method of insulin delivery into the patient's organism, and an alternative to multiple injections.
About the Authors
Y. I. Filippov
Endocrinological Scientific Centre, Russia’s Ministry of Health
Russian Federation
Russian Federation
A. Y. Mayorov
Endocrinological Scientific Centre, Russia’s Ministry of Health
Russian Federation
Russian Federation
References
1. Minocci A, Savia G, Lucantoni R et al. Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obes Relat MetDis, 2003;24:1139-1144.
2. Iwaki M, Matsuda M, Maeda N et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 2003;52:1655-1663.
3. Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta., 2013;417:80-84.
4. Schaffer JE. Lipotoxicity: when tissues overeat. Current Opinion in Lipidology, 2003;14:281-287.
5. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest, 1996;97:2859-2865.
6. Belfort R, Mandarino L, Kashyap S et al. Dose response effect of elevated plasma FFA on insulin signaling. Diabetes, 2005;54:1640-1648.
7. Pagel-Langenickel I, Bao J, Pang L, Sack MN. The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance. Endocr Rev, 2010;31:25-51.
8. Muoio DM. Intramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused? Biochim Biophys Acta, 2010;1801:281-288.
9. Mason TM, Goh T, Tchipashvili V, Sandhu H. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes, 1999;48:524-530.
10. Boden G, Chen X, Rosner J, Barton M. Effects of a 48 hour fat infusion on insulin secretion and glucose utilization. Diabetes, 1995;44:1239-1242.
11. McLaughlin T, Abbasi F, Lamendola C, Kim HS, Reaven GM. Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. Metabolism, 2001;50:819-824.
12. Mingrone G, DeGaetano A, Greco AV, Capristo E, Benedetti G, Castagneto M. Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia, 1997;40:599-605.
13. Kashyap S, Belfort R, Gastaldelli A et al. A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes. Diabetes, 2003;52:2461-2474.
14. Pankow JS, Duncan BB, Schmidt MI Fasting Plasma Free Fatty Acids and Risk of Type 2 Diabetes. Diabetes Care, 2004;27:77-82.
15. Reaven GM, Hollenbeck C, Jeng CY et al. Measurement of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 h in Patients With NIDDM. Diabetes, 1988;37:1020-1024.
Review
For citations:
Filippov YI, Mayorov AY. Insulin pump therapy for diabetes mellitus: nothing new, though familiar. Meditsinskiy sovet = Medical Council. 2013;(6):92-98. (In Russ.) https://doi.org/10.21518/2079-701X-2013-6-92-98
Views:
437
Email this article 